Clinical Trials Sponsored by Aziyo Biologics, Inc.

Total 192 results

Aziyo Biologics, Inc.

Completed

Comparison of Participants Who Received a CanGaroo® Envelope, TYRX™ Envelope, or no Envelope During CIED Implantation (HEAL)

Cardiac Disease

United States
Aziyo Biologics, Inc.

Completed

Evaluation Of New Onset Postoperative Atrial Fibrillation

Atrial Fibrillation New Onset

United States
Aziyo Biologics, Inc.

Active, not recruiting

CanGaroo® Registry Study

Arrhythmias, Cardiac

United States
Aziyo Biologics, Inc.

Completed

A Retrospective Breast Reconstruction Study

Breast Cancer

United States
Aziyo Biologics, Inc.

Completed

Obtain Additional Information on Use of CorMatrix ECM (Extracellular Matrix) (RECON)

Coronary Disease

United States
Aziyo Biologics, Inc.

Completed

A Post Market Study on the Use of Cormatrix® Cangaroo ECM® (Extracellular Matrix) Envelope (SECURE)

Cardiovascular Disease

United States
Aziyo Biologics, Inc.

Completed

ViBone in Cervical and Lumbar Spine Fusion

Degenerative Disc Disease | Cervical Spondylosis | Spondylosis | Spondylolisthesis | Herniated Nucleus Pulposus

United States
Aziyo Biologics, Inc.

Completed

CorMatrix ECM for Carotid Repair Following Endarterectomy Registry

Carotid Stenosis

United States
Aziyo Biologics, Inc.

Completed

Retrospective Experience Of CIED Implantation

Coronary Artery Disease | Heart Failure | Cardiac Disease

United States
Aziyo Biologics, Inc.

Completed

A Study on the Use of CorMatrix® ECM® for Femoral Arterial Reconstruction (PERFORM)

Peripheral Vascular Disease
Aziyo Biologics, Inc.

Withdrawn

CIED Implantation in Low BMI Patients

Heart Diseases | Cardiac Disease
Aziyo Biologics, Inc.

Withdrawn

A Study to Obtain Additional Information on the Use of CorMatrix® CanGaroo ECM® Envelope (JUMP)

Coronary Disease
Aziyo Biologics, Inc.

Withdrawn

A Study Evaluating 3-Level OLIF Spine Fusion

Degenerative Disc Disease | Spondylolisthesis | Retrolisthesis
CanSino Biologics Inc.

Recruiting

A Clinical Trial of Adsorbed Cell-free DPT Vaccine (5-component) (for People Aged 6 Years and Above)

Pertussis | Tetanus | Diphtheria

China
CanSino Biologics Inc.

Active, not recruiting

A Clinical Trial of ACYW135 Group Meningococcal Polysaccharide Conjugate Vaccine (CRM197 Vector) in a 4 to 6 Year-old Population

Epidemic Meningitis

China
VIVEX Biologics, Inc.

Terminated

Wound Healing Following Penile Prosthesis Implant

Erectile Dysfunction

United States
CanSino Biologics Inc.

Active, not recruiting

Clinical Trial of Recombinant Pneumococcal Protein Vaccine

Respiratory Tract Infections | Respiratory Tract Diseases | Pneumonia

China
CanSino Biologics Inc.

Active, not recruiting

Phase II Clinical Trial of COVID-19 mRNA Vaccine in Adults Aged 18 Years and Older

COVID-19

China
CanSino Biologics Inc.

Completed

IH Convidecia as Second Booster Dose Against Breakthrough Infections

COVID-19

Malaysia
CanSino Biologics Inc.

Withdrawn

A Study to Evaluate the Safety and Immunogenicity of Ad5-vector Based Vaccine Against Coronavirus Variants in Adults (≥18 Years) Immunized With 2 Doses of mRNA Vaccines Plus One Dose of Booster AZD1222 Vaccine

COVID-19
Qu Biologics Inc.

Terminated

QBECO SSI for Clinical and Endoscopic Remission in Moderate to Severe Crohn's Disease

Crohn Disease

Canada
Synthetic Biologics Inc.

Completed

A Study Evaluating the Effect of Esomeprazole on SYN-004 Degradation of Ceftriaxone In Adults With an Ileostomy

Healthy Volunteers With Ileostomy

Canada
Precision Biologics, Inc

Completed

QUILT-3.019: Phase 2 Study of NPC-1C Chimeric Monoclonal Antibody to Treat Pancreatic and Colorectal Cancer

Metastatic Colorectal Cancer | Metastatic Pancreatic Cancer

United States
Qu Biologics Inc.

Completed

Safety and Treatment Effect of QBECO in Moderate to Severe Crohn's Disease

Crohn's Disease | Inflammatory Bowel Disease

Canada
MLM Biologics Inc.,

Unknown

Bio-ConneKt Wound Dressing for Treatment of Chronic Leg Wounds: A Pilot Study

Skin Ulcer
Pinnacle Biologics Inc.

Withdrawn

Efficacy and Safety of a Sunscreen Against Porfimer Sodium-induced Phototoxicity to Visible Light

Esophageal Cancer | Non Small Cell Lung Cancer | High-grade Dysplasia in Barrett Esophagus
Pinnacle Biologics Inc.

Withdrawn

Safety of Photodynamic Therapy (PDT) in the Ablation of High-grade Dysplasia (HGD) in Barrett's Esophagus (BE) (Oedisse)

Barrett Esophagus
Forge Biologics, Inc

Not yet recruiting

Long-term Follow-up Study to Evaluate Safety and Efficacy of FBX-101 in Krabbe Patients

Krabbe Disease
CanSino Biologics Inc.

Not yet recruiting

A Clinical Trial of ACYW135 Group Meningococcal Polysaccharide Conjugate Vaccine (CRM197 Vector) in 18-59 Year Olds

Meningococcal Meningitis
CanSino Biologics Inc.

Recruiting

A Clinical Trial to Evaluate the Safety and Immunogenicity of a Single Dose of Adsorbed Tetanus Vaccine in a Population Aged 18 Years and Over

Tetanus

China
VIVEX Biologics, Inc.

Recruiting

Via Disc Nucleus Pulposus Older Patients Pilot

Low Back Pain | Degenerative Disc Disease | Disc Degeneration

United States
Forge Biologics, Inc

Active, not recruiting

Gene Transfer Clinical Trial for Krabbe Disease (RESKUE)

Krabbe Disease

United States
CanSino Biologics Inc.

Active, not recruiting

A Clinical Trial of Diphtheria, Tetanus and Acellular Pertussis (Three Components) Combined Vaccine, Adsorbed(DTcP)

Diphtheria, Tetanus and Acellular Pertussis

China
ILIAS Biologics Inc.

Completed

A Study to Evaluate the Safety and Tolerability of ILB-202

Healthy

Australia
ADMA Biologics, Inc.

Completed

Study to Evaluate Safety and Pharmacokinetics of BIVIGAM® in Primary Immune Deficiency Subjects Aged 2 to 16

Humoral Immune Response

United States
ADMA Biologics, Inc.

Active, not recruiting

A Study About Low Blood Pressure in Patients With Primary Immunodeficiency Disease Treated With Immune Globulin Products

Primary Immune Deficiency Disorder

United States
ADMA Biologics, Inc.

Completed

Open Label, Phase III Study of NABI-IGIV 10% [Immune Globulin Intravenous(Human), 10%] In Subjects With Primary Immune Deficiency Disorders (PIDD)

Primary Immune Deficiency Disorders (PIDD)

United States
VIVEX Biologics, Inc.

Active, not recruiting

Viable Allograft Supplemented Disc Regeneration in the Treatment of Patients With Low Back Pain (VAST)

Degenerative Disc Disease

United States
TaiMed Biologics Inc.

Completed

Ibalizumab Plus Optimized Background Regimen in Patient With Multi-Drug Resistant HIV

HIV

United States, Taiwan, Puerto Rico
Synthetic Biologics Inc.

Completed

A Study to Evaluate the Effect of SYN-004 on the PK of IV Ceftriaxone in Adults With a Functioning Ileostomy

Healthy Volunteers

Canada, United States
Synthetic Biologics Inc.

Completed

A Study of the Effect of SYN-010 on Subjects With IBS-C

Irritable Bowel Syndrome With Constipation (IBS-C)

United States
Qu Biologics Inc.

Withdrawn

Single and Multiple Dose Evaluation of QBKPN SSI In Healthy Volunteers

Healthy
ADMA Biologics, Inc.

Completed

Pharmacokinetics, Efficacy, and Safety Study of RI-002 (IGIV) in Subjects With Primary Immunodeficiency Diseases (PIDD)

Primary Immune Deficiency Disorder

United States
TaiMed Biologics Inc.

Completed

Dose-Response Study of Ibalizumab (Monoclonal Antibody) Plus Optimized Background Regimen in Patients With HIV-1 (TMB-202)

HIV

Puerto Rico, United States
Aperion Biologics, Inc.

Unknown

Safety and Efficacy Study of the Z-Lig Medical Device Compared to Allograft (Z-Lig)

Ruptured Anterior Cruciate Ligaments

Italy, Belgium, Denmark, Netherlands, South Africa, Spain
ADMA Biologics, Inc.

Completed

RI-001 in Immunosuppressed Respiratory Syncytial Virus (RSV) Infected Patients at Risk of Lower Tract RSV Illness

Lower Respiratory Tract Infection | Upper Respiratory Tract Infection

United States, Canada
Pinnacle Biologics Inc.

Withdrawn

Case Analysis on Real Life Incidence of Photodynamic Therapy (PDT) Safety Outcomes (CALIPSO)

Esophageal Cancer | Lung Cancer | Barrett's Esophagus
CanSino Biologics Inc.

Not yet recruiting

A Clinical Trial to Evaluate the Immunogenicity and Safety of Group ACYW135 Meningococcal Conjugate Vaccine (CRM197) in Adults Aged 18 to 55 Years

Meningococcal Meningitis

Indonesia
CanSino Biologics Inc.

Recruiting

A Study to Evaluate the Safety and Immunogenicity of ChAdOx1-VZV in Healthy Adults Aged 50-65 Years

Herpes Zoster

Canada
CanSino Biologics Inc.

Recruiting

Phase IV Clinical Study of Immunogenicity of ACYW135 Group Meningococcal Polysaccharide Conjugate Vaccine (CRM197 Vector)

Epidemic Meningitis

China

3

Subscribe